SUO Annual Meeting

Over half of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

The in-depth interview covers the data that led to the NMIBC approval, outlines the appropriate patient population for pembrolizumab, and reviews side-effect management with the immune checkpoint inhibitor.

Researchers examined the prevalence of germline mutations, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

Clinical activity with MK-6482 was observed in both RCC and non-RCC lesions.

The algorithm was applied to 50 patients who underwent radical prostatectomy between 2008 and 2018.

Ten-year data showed high overall survival and recurrence-free survival rates with Mohs surgery in patients with localized penile cancer.

The app also provides patients with a socially distant alternative to in-person visits during the COVID-19 pandemic.

Cancer-specific survival is noninferior for active surveillance compared with primary intervention in select patients with small renal masses suspicious for renal cell carcinoma.

Blue light cystoscopy identified patients with bladder cancer recurrence post-BCG that would have been missed with standard white light cystoscopy alone.

A separate analysis presented at SUO assessed the impact of nadofaragene firadenovec on the incidence and time to cystectomy.

Arjun V. Balar, MD, walks through the patient discussion when weighing the use of pembrolizumab (Keytruda).

Of 13 studies evaluated by investigators for the meta-analysis, only 1 was a randomized controlled trial.

Physicians involved in clinical trials should have the patient in mind “from the very conception of the design to the conduct of the study to dissemination of the results,” says Angela B. Smith, MD, MS.

The researchers also determined that healthcare disparities were associated with cystectomy delay.

The vast majority of patients reported being "pleased" with their medical encounter.

The majority of patients surveyed reported having at least some interest in sexual activity following surgery.

Combining the 4Kscore or ExoDx with multiparametric MRI appears to be the optimal strategy for detecting high-grade prostate cancer, a study from the University of California, San Francisco suggests. However, it is reasonable to consider biomarker testing only in patients who want to avoid biopsy, said first author Claire M. de la Calle, MD.

Clinicians are taught that renal cell carcinoma is radioresistant, but modalities such as stereotactic body radiation therapy (SBRT) can be safe and efficacious in certain patients with RCC. In this interview, Vitaly Margulis, MD, outlines the advantages of SBRT and offers a preview of the RADVAX trial, which combines radiotherapy and immunotherapy.

The Cancer Genome Atlas (TCGA) has provided a “complete genomic roadmap” of muscle-invasive bladder cancer, according to Seth P. Lerner, MD, co-chair of the Analysis Working Group of the TCGA program for muscle-invasive bladder cancer. Dr. Lerner talks to Urology Times about the clinical relevance of the TCGA’s findings, possible implications for upper tract disease, and what further research is needed.

The introduction of targeted therapies and immunotherapies has generated uncertainty regarding the role of the cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma. In this interview, Hyung L. Kim, MD, discusses the recent CARMENA and SURTIME clinical trials, and outlines the upcoming SWOG-1931 trial.

In a pivotal phase III study, more than half of patients with high-grade nonmuscle-invasive bladder cancer (carcinoma in situ ± Ta/T1) receiving nadofaragene firadenovec achieved a complete response at 3 months, reported lead author Colin P.N. Dinney, MD.

Christopher Sweeney, MBBS, outlines a handful of important questions to ask when deciding which systemic therapy to select for which patient with metastatic hormone-sensitive prostate cancer.

“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” says Alexandre Zlotta, MD, PhD, in this video.

“Over the past few decades, the rate of active surveillance has been around 10%. Now in recent years, the rate of active surveillance is 55% across the U.S. So times are changing," says Sigrid Carlsson, MD, PhD, MPH, in this interview.

In this video, Viraj Master, MD, offers the latest evidence and his recommendations for managing synchronous and metachronous disease in the face of renal cell carcinoma, including the role of metastasectomy.

In this video interview with Urology Times, Arjun V. Balar, MD, PhD, discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of recently presented phase II study data.

“Urologists can play an active role in reducing the opioid epidemic just by prescribing fewer opioids,” says Kathryn Hacker Gessner, MD, PhD, in this video.

In this video, Todd M. Morgan, MD, talks about the still-uncertain future of imaging in advanced prostate cancer.

In a video interview with Urology Times, Robert C. Flanigan, MD, points out the shortcomings of the CARMENA trial, patient selection for cytoreduction, and the future of cytoreductive nephrectomy in the age of PD-1 inhibitors.

In this video, Inderbir S. Gill, MD, discusses data comparing multiple parameters, including intraoperative, perioperative, oncologic, and functional outcomes of open versus robotic surgery